Temsirolimus

Temsirolimus (also known as CCI-779) is a recently developed mTOR inhibitor, with improved aqueous solubility and more favorable pharmaceutical properties compared with the parent compound rapamycin.
Temsirolimus has shown promising preclinical and early clinical antitumor activity and is currently in phase III clinical development for the treatment of different solid tumors, including breast cancer.